公开(公告)号：WO2019089365A1

公开(公告)日：2019-05-09

申请号：PCT/US2018/057650

申请日：2018-10-26

Applicant: ENTERIN LABORATORIES, INC.

Inventor： KINNEY, William A. ,  ZASLOFF, Michael ,  KUMAR, Anil ,  ZELELLOW, Amanuel Z. ,  ZHAO, Dalian

IPC: C07J31/00 ,  A61K31/575 ,  A61P31/04 ,  A61P31/10 ,  A61P35/00

CPC classification number: C07J41/0005 ,  C07B2200/13

Abstract: Provided herein are crystalline solid forms of squalamine phosphate designated as Form 1 and Form 2, compositions containing one or both forms, and methods of their preparation and of their use.

公开(公告)号：WO2019050903A1

公开(公告)日：2019-03-14

申请号：PCT/US2018/049482

申请日：2018-09-05

Applicant: ENTERIN LABORATORIES, INC.

Inventor： BARBUT, Denise ,  ZASLOFF, Michael

IPC: A61K31/575 ,  A61P25/20

CPC classification number: A61K31/575 ,  A61K9/0043 ,  A61K9/0053 ,  A61K35/60 ,  A61P43/00

Abstract: This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.

公开(公告)号：WO2018222665A1

公开(公告)日：2018-12-06

申请号：PCT/US2018/035054

申请日：2018-05-30

Applicant: ENTERIN LABORATORIES, INC.

Inventor： BARBUT, Denise ,  STOLZENBERG, Ethan ,  ZASLOFF, Michael

IPC: A61K39/395 ,  A61P29/00 ,  A61K39/00

CPC classification number: A61K31/575 ,  A61K2039/505 ,  A61K2300/00 ,  A61P29/00 ,  C07K16/2845 ,  C12N15/113 ,  G01N33/6863 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/2835

Abstract: Described are methods of treating or preventing an inflammatory disease or condition caused by excessive expression, secretion, or concentration of alpha synuclein. The methods comprise administering compositions that reduce the effective concentration of alpha-synuclein present in the surrounding tissues. In addition, the invention encompasses methods of inhibiting alpha-synuclein interaction with CD11b, comprising administering an agent that binds to alpha-synuclein to prevent binding productively to the integrin CD11b, or administering an active agent that interacts with CD11b on an immune cell to prevent alpha-synuclein from directing chemotaxis of that cell. In addition, the invention discloses a method of identifying an individual with a condition amenable to treatment targeting alpha-synuclein CD11b interaction.